Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) was down 0.2% on Thursday . The company traded as low as $791.50 and last ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

and online pharmacies have seen a shift to Mounjaro prescriptions. Ro, a telehealth company, has teamed up with Eli Lilly to improve patient access to Zepbound (tirzepatide). Through LillyDirect ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating ...

Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...

Musk revealed using Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, highlighting their ... stock crashed by 19% on Dec. 20, after the company reported results from a late-stage clinical trial ...

The obesity drug race is heating up in more ways than one.Eli Lilly, the world’s biggest pharmaceutical company by market ...

Eli Lilly and Company (NYSE: LLY ... Weekly tirzepatide (Zepbound® and Mounjaro®) injections (pooled 5 mg, 10 mg, 15 mg doses) significantly reduced the risk of progression to type 2 diabetes ...